Catabolism of Purines - Exhaustive Study Guide

Overview of Nucleic Acid Degradation

• Continuous Process: The breakdown of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) occurs continuously within the cell.
• Dual Pathways for Components: Purine and pyrimidine nucleosides resulting from breakdown have two possible pathways:
  • Degradation: They can be broken down further into waste products and excreted from the body.
  • Salvage: They can be salvaged and reused as nucleotide components.

Sequence of Reactions in Purine Nucleotide Degradation

• Primary Location: Purine degradation takes place primarily in the human liver.
• Enzymatic Requirement: A specific assortment of enzymes is required to progressively degrade purines into the final waste product, uric acid.
• Pathway Steps for Nucleotide Monophosphates:
  • Step 1: Nucleotide to Nucleoside Conversion: The nucleotide monophosphates—Adenosine Monophosphate ($AMP$), Inosine Monophosphate ($IMP$), Xanthosine Monophosphate ($XMP$), and Guanosine Monophosphate ($GMP$)—are converted into their respective nucleoside forms by the enzyme nucleotidase.
    • $AMP \rightarrow \text{Adenosine}$
    • $IMP \rightarrow \text{Inosine}$
    • $XMP \rightarrow \text{Xanthosine}$
    • $GMP \rightarrow \text{Guanosine}$
    • Reaction releases an inorganic phosphate ($P_i$).
  • Step 2: Deamination: Amino groups can be removed from either $AMP$ or Adenosine.
    • $AMP$ is converted to $IMP$ by $AMP \text{ deaminase}$.
    • Adenosine is converted to Inosine by Adenosine Deaminase ($ADA$), releasing ammonia ($NH_4^+$).
  • Step 3: Nucleoside to Purine Base Conversion: The nucleosides Inosine, Xanthosine, and Guanosine are converted into their corresponding free purine bases by the enzyme Purine Nucleoside Phosphorylase ($PNP$).
    • $\text{Inosine} + P_i \rightarrow \text{Hypoxanthine} + \text{Ribose-1-phosphate}$
    • $\text{Xanthosine} + P_i \rightarrow \text{Xanthine} + \text{Ribose-1-phosphate}$
    • $\text{Guanosine} + P_i \rightarrow \text{Guanine} + \text{Ribose-1-phosphate}$
    • Crucial Limitation: Adenosine is not a substrate for $PNP$. Therefore, it must first be converted to Inosine via $ADA$ to proceed through the degradation pathway.
  • Step 4: Base Modification to Xanthine:
    • Hypoxanthine: Is converted to Xanthine by the enzyme Xanthine Oxidase.
    • Guanine: Undergoes deamination by the enzyme Guanase (also called Guanine Deaminase) to form Xanthine, releasing $NH_4^+$ in the process.
  • Step 5: Formation of Uric Acid: Xanthine Oxidase converts Xanthine into Uric Acid.

Characteristics of Key Catabolic Enzymes

• Xanthine Oxidase (XO):
  • Classification: It is a metallo-flavoprotein.
  • Cofactors: It contains Flavin Adenine Dinucleotide ($FAD$), Molybdenum ($Mo$), and Iron ($Fe$).
  • Tissue Distribution: It is found exclusively in the liver and the small intestine.
  • Byproducts: The reaction catalyzed by Xanthine Oxidase liberates Hydrogen Peroxide ($H_2O_2$), which is harmful to biological tissues.
• Catalase:
  • Function: Cleaves the harmful $H_2O_2$ produced by Xanthine Oxidase into water ($H_2O$) and oxygen ($O_2$) to protect tissues.

Absorption and Excretion of Uric Acid

• Sources of Uric Acid:
  • Endogenous Production: Approximately two-thirds of uric acid is produced within the body through normal metabolic processes.
  • Exogenous Production: Approximately one-third is produced from external sources, specifically diet.
• Dietary Influences: Purines are high in certain foods which can elevate uric acid levels:
  • Red meat and organ meats (e.g., liver).
  • Seafood (e.g., sardines, trout, and tuna).
  • Alcoholic beverages, with beer being a significant contributor.
  • Drinks sweetened with fruit sugar (fructose).
• Excretion Mechanisms:
  • Renal Route (Kidneys): Most uric acid ($75\%$) leaves the body via urine.
    • Uric acid is filtered through the glomeruli.
    • A significant amount ($90-95\%$) is reabsorbed by transporters in the proximal renal tubules.
    • Remaining excretion occurs in the urine; notably, more than $80\%$ of urinary uric acid is derived from distal tubular secretion.
    • Gender Difference: Urinary excretion is slightly lower in males than in females, contributing to a higher incidence of hyperuricemia in men.
  • Intestinal Route: The remaining $25\%$ of urate passes into the intestinal lumen.
    • Uricolysis: Intestinal bacteria break down this uric acid.
• Homeostasis: The human body normally maintains a strict balance between the absorption/production and the excretion of uric acid.

Clinical Significance: Hyperuricemia

• Definition: Hyperuricemia is the accumulation of uric acid in the blood when excretion is insufficient to match production.
• Diagnostic Thresholds:
  • Men: Serum Uric Acid ($UA$) $> 7.0\,mg/dL$ ($0.42\,mmol/L$).
  • Women: Serum Uric Acid ($UA$) $> 6.0\,mg/dL$ ($0.36\,mmol/L$).
• Normal Blood Levels:
  • Males: $3-7\,mg/dL$.
  • Females: $2-6\,mg/dL$.
• Mechanisms of Development:
  • Underexcretors: Decreased renal excretion (accounts for the majority of cases). This can involve decreased glomerular filtration, decreased tubular secretion, or enhanced tubular reabsorption.
  • Overproducers: Increased production or release into the plasma exceeding renal clearance capacity.
  • Combined Mechanism: A combination of increased production and decreased excretion.

Gout Arthritis

• Pathophysiology: Chronic hyperuricemia leads to serum urate levels exceeding their solubility limit. This results in the formation of sharp, needlelike sodium urate crystals in joints or surrounding soft tissues.
• Clinical Manifestation:
  • Gout is the clinical manifestation of these high levels.
  • Characterized by sudden attacks of severe swelling, pain, redness, and inflammation.
  • Commonly affects the big toe.
• Treatment and Management:
  • Dietary Control: Avoidance of purine-rich foods (e.g., caviar/fish eggs) to prevent exacerbation.
  • Pharmacological Intervention (Allopurinol):
    • Mechanism: Allopurinol is a hypoxanthine analog that acts as a Xanthine Oxidase inhibitor.
    • Action: It binds tightly to Xanthine Oxidase, blocking its action through substrate competition.
    • Outcome: This prevents the formation of uric acid. Instead, hypoxanthine and xanthine accumulate. Because these precursors are more soluble than uric acid, they do not reach harmful concentrations and are easily excreted.

Lesch-Nyhan Syndrome

• Etiology: A metabolic disorder caused by a complete deficiency of the enzyme Hypoxanthine-Guanine Phosphoribosyltransferase ($HGPRT$).
• Genetics: It is a congenital, recessive, sex-linked trait that is manifested only in males.
• Biochemical Impact:
  • Lack of $HGPRT$ prevents the salvage of hypoxanthine and guanine.
  • This leads to a lack of consumption of Phosphoribosyl Pyrophosphate ($PRPP$).
  • Elevated $PRPP$ levels increase the activity of glutamine-$PRPP$ amidotransferase, dramatically enhancing de novo purine biosynthesis.
  • The end result is a massive increase in uric acid production, leading to hyperuricemia and hyperuricosuria (uric acid in urine).
• Clinical Symptoms:
  • Crippling gouty arthritis.
  • Severe nervous system malfunctions: mental retardation and spasticity.
  • Behavioral Indicators: Aggressive behavior and self-mutilation (e.g., biting fingers/lips and head banging).
  • Physical Disability: Patients usually cannot walk, require assistance sitting, and generally use wheelchairs.

Purine Salvage Pathways

• Function: Recycling purine bases into nucleotides to save energy and manage metabolite levels.
• Key Enzymes:
  • Adenine Phosphoribosyltransferase (APRT): Converts Adenine + $PRPP \rightarrow AMP + PP_i$.
  • Hypoxanthine-Guanine Phosphoribosyltransferase (HGPRT):
    • Converts Hypoxanthine + $PRPP \rightarrow IMP + PP_i$.
    • Converts Guanine + $PRPP \rightarrow GMP + PP_i$.